Provided by Tiger Trade Technology Pte. Ltd.

Insulet

224.66
+4.822.19%
Volume:1.12M
Turnover:252.60M
Market Cap:15.80B
PE:64.57
High:229.94
Open:222.80
Low:219.89
Close:219.84
52wk High:354.88
52wk Low:216.49
Shares:70.35M
Float Shares:70.08M
Volume Ratio:0.98
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.48
EPS(LYR):3.48
ROE:18.12%
ROA:9.43%
PB:10.43
PE(LYR):64.57

Loading ...

U.S. Earnings Preview: Before Market Open Feb. 18

Dow Jones
·
Feb 18

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 18

Assessing Insulet (PODD) Valuation After Omnipod 5 And Data Platform Expansion In The Middle East

Simply Wall St.
·
Feb 16

Insulet Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Feb 13

Earning Preview: Insulet revenue is expected to increase by 31.89% this quarter, and institutional views are predominantly bullish

Earnings Agent
·
Feb 11

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 10

BTIG Keeps Their Buy Rating on Insulet (PODD)

TIPRANKS
·
Feb 05

Insulet bringt Omnipod 5 und Omnipod Discover in den Nahen Osten

Reuters
·
Feb 05

Stifel Adjusts Price Target on Insulet to $350 From $370, Maintains Buy Rating

MT Newswires Live
·
Feb 05

Insulet Extends Key Supply Agreement with NXP USA

TIPRANKS
·
Feb 04

Insulet Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Feb 04

Insulet Corporation verlängert Liefervertrag mit NXP USA

Reuters
·
Feb 04

Insulet’s Omnipod M Study Completes Key Milestone in Type 2 Diabetes Onboarding

TIPRANKS
·
Jan 31

Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jan 28

Insulet Corp. Stock Slides 3.0%, Underperforms Peers

Dow Jones
·
Jan 24

Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase

TIPRANKS
·
Jan 23

Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Gilead Sciences (GILD)

TIPRANKS
·
Jan 22

Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jan 21

Goldman Sachs Adjusts Price Target on Insulet to $363 From $365, Maintains Buy Rating

MT Newswires Live
·
Jan 16

Insulet Corporation highlights diabetes management leadership and market growth in new investor presentation

Reuters
·
Jan 14